SAN DIEGO, Dec. 16 Sequenom, Inc. (Nasdaq: SQNM), today announced the appointment of Dr. Kenneth Buechler and Mr. David Pendarvis to its board of directors.
Kenneth F. Buechler, Ph.D., was president, chief scientific officer and co-founder of Biosite Incorporated. From 1988 to 1994, Dr. Buechler was Biosite's director of chemistry. Prior to forming Biosite, Dr. Buechler was a senior research scientist for the diagnostics research and development group at Hybritech Incorporated in San Diego. Dr. Buechler received his doctorate in biochemistry and his bachelor's degree in chemistry from Indiana University. Dr. Buechler sits on the boards of Quidel Corp., Sotera Wireless Inc., Adnavance Inc., and Astute Medical Inc.
David Pendarvis is senior vice president - organizational development, global general counsel and secretary of ResMed Inc., a medical device company focused on sleep-disordered breathing. He has been with ResMed since 2002. From 2000 until 2002, Mr. Pendarvis was a partner in the law firm of Gray Cary Ware & Freidenrich LLP. Until 2000 he was a partner with Gibson, Dunn & Crutcher LLP, where he began working in 1986. From 1984 until 1986 he was a law clerk to the Hon. J. Lawrence Irving, US District Judge, Southern District of California. Mr. Pendarvis received his J.D. from the University of Texas School of Law, a MS in executive leadership from the University of San Diego, and a BA from Rice University.
"I am delighted that Ken and David have agreed to join our board of directors," said Dr. Harry Hixson, interim chief executive officer at Sequenom. "The talent and diverse expertise of our board has always been one of Sequenom's assets. With their proven industry executive experience, Ken and David are key additions to our team."
Dr. Buechler and Mr. Pendarvis join existing board members Dr. Ernst-Gunter Afting, Dr. Charles Cantor, Mr. John Fazio, Dr. Harry Hixson, Dr. Richard Lerner, Dr. Ronald Lindsay and Ms. Kathleen Wiltsey.
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.
SEQUENOM(®) is a registered trademark of Sequenom, Inc.
SOURCE Sequenom, Inc.